Clinical Trials Logo

Leukemia, Myeloid, Chronic-Phase clinical trials

View clinical trials related to Leukemia, Myeloid, Chronic-Phase.

Filter by:

NCT ID: NCT06229860 Recruiting - Clinical trials for Chronic Myeloid Leukemia

Impact of Personality on Adherence to Tyrosine Kinase Inhibitor Therapy in Pts w/Chronic Myeloid Leukemia

Start date: January 25, 2024
Phase:
Study type: Observational

This is an observational pilot study to examine the association between a patient's personality and adherence to tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia.

NCT ID: NCT06121765 Not yet recruiting - CML, Chronic Phase Clinical Trials

Metabolic Alternation and Clinicohematological Characteristic in Chronic Phase CML in Patient Treated With TKI

Start date: November 1, 2023
Phase:
Study type: Observational

Metabolic alternation and clinicohematological characteristic in chronic phase CML in patient treated with TKI

NCT ID: NCT06082804 Recruiting - Clinical trials for Chronic Myelogenous Leukemia - Chronic Phase

Evaluation of Advanced Practice Nurse's Management of Patients With Chronic Myeloid Leukemia

IPA-LMC
Start date: November 29, 2023
Phase: N/A
Study type: Interventional

Chronic Myeloid Leukemia (CML) affects 820 people per year in France (2018), half of them are older than 60 years old. Tyrosine Kinase Inhibitors (TKI) are new kind of targeted therapy whose efficiency allow for a high rate of complete molecular response, leading to a disruption of treatment under certain conditions. Optimizing CML treatment is a major concern, particularly for adverse events management, treatment compliance and therapeutic response. Multiple studies demonstrated that grade ≤ II adverse events are most likely to be under reported by patients and clinicians. Although these adverse events are mostly reported by clinical examination, needing minimal treatment. These toxicities could alter daily and domestic living activities, potentially impacting treatment compliance and therapeutic response. Therefore, early detection of these adverse events is a major challenge for the prognosis and care of CML. The Advanced Practice Nurse (APN), a new health care professional, acquired the skills needed to independently follow, manage and care the patients with medical approvals. At international level, many studies, in oncology and in others domains, have been done to demonstrate the added value of the APN, particularly in improving patient's quality of life, management, care of drug-induced adverse events and treatment compliance. In France, because of the recentness of the profession, only few studies were have been conducted. The goal of this study is to demonstrate the benefit of APN in clinical follow-up, quality of life, treatment compliance, and therapeutic response of CML patients. These effects could be managed thanks to early detection and management of ≤ grade II adverse events during consultation, in partnership with the patients, and in collaborative working.

NCT ID: NCT05794880 Recruiting - Leukemia Clinical Trials

MCW Alpha/Beta T-Cell and B-Cell Depletion With Targeted ATG Dosing

Start date: May 1, 2023
Phase: N/A
Study type: Interventional

This is a single arm pilot study for patients with hematologic malignancies receiving unrelated or haploidentical related mobilized peripheral stem cells (PSCs) using the CliniMACS system for alpha/beta T cell depletion plus CD19+ B cell depletion with individualized ALC-based dosing of ATG to study impact on engraftment, GVHD, and disease free survival

NCT ID: NCT05384587 Recruiting - Clinical trials for Chronic Myelogenous Leukemia - Chronic Phase

Asciminib Monotherapy, With Dose Escalation, for 2nd and 1st Line Chronic Myelogenous Leukemia

ASC2ESCALATE
Start date: November 11, 2022
Phase: Phase 2
Study type: Interventional

This will be a multicenter Phase II open-label study of asciminib in CML-CP patients who have been previously treated with one prior ATP- binding site TKI with discontinuation due to treatment failure, warning or intolerance. (2L patient cohort). In addition, newly diagnosed CML-CP patients who may have received up to 4 weeks of prior TKI are included in a separate 1L patient cohort.

NCT ID: NCT05367765 Not yet recruiting - CML, Chronic Phase Clinical Trials

A Real World Study of the Efficacy and Safety of Flumatinib Versus Imatinib in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase

Start date: April 30, 2022
Phase: Phase 4
Study type: Interventional

Flumatinib is an orally available TKI with high selectivity and potency against BCR-ABL1 kinase. It's a multi-center, open-label, real world study to explore the efficacy and safety of Flumatinib versus Imatinib as the first line therapy in patients with chronic myleiod leukemia(CML) in chronic phase(CP).

NCT ID: NCT05367700 Recruiting - CML, Chronic Phase Clinical Trials

A Study of HS-10382 in Patients With Chronic Myeloid Leukemia.

Start date: April 28, 2022
Phase: Phase 1
Study type: Interventional

HS-10382 is a small molecular, oral potent, allosteric inhibitor. By binding a myristoyl site of the BCR-ABL1 protein, HS-10382 locks BCR-ABL1 into an inactive conformation. The purpose of this study is to investigate the safety/tolerability and the pharmacokinetic(PK) profile of HS-10382 in patients with chronic myeloid leukemia (CML). Anti-CML activity will also be investigated in this study.

NCT ID: NCT05353205 Recruiting - CML, Chronic Phase Clinical Trials

A Study of the Efficacy and Safety of Flumatinib in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase.

Start date: November 23, 2021
Phase: Phase 4
Study type: Interventional

It's a double-blind , randomized ,multi-center study. The purpose of this study is to explore the efficacy and safety of flumatinib 400mg once daily (QD) versus 600mg QD as the first line therapy in patients with chronic myleiod leukemia(CML) in chronic phase(CP).

NCT ID: NCT05007873 Recruiting - Clinical trials for Chronic Phase Chronic Myelogenous Leukemia

ASTX727 and Dasatinib for the Treatment of Newly Diagnosed Philadelphia Chromosome or BCR-ABL Positive Chronic Myeloid Leukemia in Chronic Phase

Start date: October 21, 2021
Phase: Phase 2
Study type: Interventional

This phase II trial studies the effect of ASTX727 and dasatinib in treating patients with newly diagnosed Philadelphia chromosome or BCR-ABL positive chronic myeloid leukemia in chronic phase. Philadelphia chromosome positive and BCR-ABL positive are types of genetic mutations (changes). Chemotherapy drugs, such as ASTX727, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Dasatinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. ASTX727 and dasatinib may help to control Philadelphia chromosome-positive chronic myeloid leukemia or BCR-ABL positive chronic myeloid leukemia in chronic phase.

NCT ID: NCT04925141 Completed - Clinical trials for Chronic Myelogenous Leukemia - Chronic Phase

A Study of Dasatinib as First-line Treatment for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia (CML-CP)

Start date: May 10, 2016
Phase: Phase 4
Study type: Interventional

The purpose of this multicenter,open, prospective and single arm study is to evaluate the efficacy and safety of domestic dasatinib in the first-line treatment of newly diagnosed CML-CP.